Ranivisio Revolution: Easier Eye Treatment Arrives in Europe

Game-Changer for Eye Treatment: Formycon launches Ranivisio, the first ranibizumab biosimilar in a pre-filled syringe in Europe, starting with France in 2025! This convenient format promises easier administration for patients, with Teva partnering to expand access across Europe. Investors are optimistic, and the return of Cimerli in the US next year could further boost Formycon's global presence, setting the stage for a shakeup in the biosimilar market.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.